AusperBio to Present Two Posters on AHB-137, a Novel Antisense Oligonucleotide for Hepatitis B at EASLâ„¢ Congress 2023

Data will highlight the preclinical antiviral activity, pharmacokinetic property, and safety profile of AHB-137, a potential best-in-class antisense oligonucleotide (ASO) for the treatment of chronic Hepatitis B (CHB). SAN FRANCISCO, June 12, 2023 /PRNewswire/ — Ausper Biopharma Co., Ltd….